Tracy MacNeal
4 September 2018Americas

Medtech M&A: integration is key

In the second quarter of 2018, 61 merger and acquisition (M&A) deals worth $119 billion in the pharma and life sciences were announced, according to consultancy firm PwC in its “Global pharma & life sciences deals insights: Q2 2018” report.

This trend has set the stage for the rest of 2018: PwC expects more “mega deals” to drive M&A activity in the second half of the year.

Also in Q2, the medical devices sector (which includes diagnostics) increased 92% in deal value with Fortive’s acquisition of Johnson & Johnson’s advanced sterilisation products business for $2.7 billion and Zoetis’s buyout of Abaxis for $2 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at